Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 7/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798769 | 1.00 | KCNN4 (0.56) | KCNN4CYP2C9CES2CES1CYP19A1 | |
| SCHEMBL28905930 | 0.96 | KCNN4 (0.57) | KCNN4CYP2C9CES2CES1CYP19A1 | |
| SCHEMBL29940807 | 0.96 | KCNN4 (0.57) | KCNN4CYP2C9CES2CES1CYP19A1 | |
| Bromomethane SCHEMBL207605 | 0.94 | KCNN4 (0.51) | KCNN4CYP2C9CES2CES1CYP19A1 | |
| SCHEMBL12350296 | 0.84 | PTPRC (0.49) | KCNN4CES2CES1NPC1MEN1 | |
| Benzylic Acid SCHEMBL3169072 | 0.83 | CES2 (0.65) | KCNN4CYP2C9CES2CES1PARP1 | |
| SCHEMBL4941607 | 0.81 | KCNN4 (0.53) | KCNN4CES2CES1CYP19A1PARP1 | |
| SCHEMBL3934832 | 0.81 | KCNN4 (0.53) | KCNN4CES2CES1CYP19A1PARP1 | |
| SCHEMBL1827704 | 0.81 | KCNN4 (0.53) | KCNN4CES2CES1CYP19A1PARP1 | |
| SCHEMBL17420738 | 0.80 | KCNN4 (0.56) | KCNN4CES2CES1CYP19A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-112279808-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112250627-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-107690281-B | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-106163517-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-110840847-A | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2020-02-28 | — | — | CN | disclosed |
| EP-2010185-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-01-07 | — | — | EP | disclosed |
| EP-2011536-A1 | Inhaler | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | disclosed |
| EP-1877376-A1 | NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20070282276-A1 | PROCESS AND DEVICE FOR DOSING PHARMACEUTICAL AGENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2006114371-A1 | NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
| US-20060134007-A1 | Blister for inhalers | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6852728-B2 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-08 | — | — | US | disclosed |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CES2 2463/4885 |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | CHRM1, CHRM3, CHRM2 | KCNN4 280/4885CYP2C9 368/4885CES2 337/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | KCNN4 1606/4885CYP2C9 1856/4885CES2 4611/4885 |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | CHRM1, CHRM3, CHRM2 | KCNN4 248/4885CYP2C9 162/4885CES2 470/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CES2 2463/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CES2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.